Drug intelligence / Profile preview

KM-133

Development stage: Unknown
Lead developer: Innovation Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

KM-133 is an investigational small-molecule drug being developed for the treatment of psoriasis. Publicly available information from Cellceutix (now Innovation Pharmaceuticals) describes KM-133 as part of the company’s dermatology pipeline, positioned as a novel oral anti-psoriatic agent, but detailed structure, specific molecular target, and full mechanism of action have not been disclosed. It has been reported as advancing toward Phase 2 clinical trials for psoriasis, suggesting completed or ongoing early-phase evaluation of safety, tolerability, and preliminary efficacy in this chronic inflammatory skin disease characterized by keratinocyte hyperproliferation and immune dysregulation.[3][7]

Beyond the preview

Go deeper on KM-133.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KM-133.

Explore the full profile